SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Joe Copia's daytrades/investments and thoughts -- Ignore unavailable to you. Want to Upgrade?


To: CoffeePot who wrote (9214)10/27/1998 11:19:00 AM
From: CoffeePot  Read Replies (1) | Respond to of 25711
 
DYGN gapping up,, theres also been quite a few insider buys biz.yahoo.com

check this chart out quote.yahoo.com

more info:

DynaGen, Inc. (Nasdaq: DYGN - news). The company manufactures, distributes and markets generic versions of pharmaceuticals after brand name patents of those drugs expire. The company announced that 1998 revenues are up from $1.2 million in 1997 to $6.4 million in 1998.

CAMBRIDGE, Mass.--(BW HealthWire)--Aug. 24, 1998--DynaGen Inc. (NASDAQ:DYGN - news; BSE:DYG) today announced that its wholly owned subsidiary, Able Laboratories Inc., has signed a multi-year supply agreement with Warner-Lambert Co. [NYSE:WLA - news], of Morris Plains, N.J., to manufacture a product for their international markets.